Anouk

Quick links to important sections

Anouk

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anouk

Quick Facts

Property Description
Active ingredient Desogestrel (INN)
Form Tablet (Film-coated)
Pharmacological class Hormonal Contraceptive; Progestogen (Progestin)
Common use Prevention of pregnancy (Contraception)
Origin Synthetic steroid (Gonane derivative)

Defining Anouk: A Progestogen-Only Contraceptive

Anouk is an oral contraceptive pill specifically designed for the highly effective prevention of pregnancy. The sole active substance is Desogestrel (INN), a synthetic steroid which defines the medicine as a Progestogen-Only Pill (POP) within the hormonal contraceptive pharmacological class. Desogestrel is a third-generation progestogen with a strong antiovulatory effect, even at low doses. This highlights the compound's high efficacy in controlling fertility through its reliable action.

This preparation is specifically intended for women seeking fertility control and is generally characterized by the complete absence of estrogen in its composition. Desogestrel, which is a member of the gonane family of synthetic progestins, works through endocrine action, resulting in mechanisms that secure a reliable defense against conception. The core, high-level purpose of this monophasic tablet is therefore to offer a daily, easily reversible method for reproductive management, often positioned for patient groups who require an estrogen-free option.

Composition and Pharmaceutical Form of Desogestrel

The pharmaceutical identity of Anouk is that of a single-ingredient, monophasic tablet intended for administration via the oral route. The active substance, Desogestrel, is specifically classified as a progestin, meaning it is a synthetic agent that acts similarly to the naturally occurring progesterone hormone in the body. This confirms its structural and functional relationship to natural hormones.

The product is formulated as a solid oral preparation, incorporating specific pharmaceutical excipients necessary to ensure stability and reliable delivery of the Desogestrel to the body. This composition, containing only the progestogen, presents a targeted hormonal profile that serves as a distinct alternative to combined oral contraceptives that utilize both progestin and estrogen. Unlike some older POPs, Desogestrel-containing formulations like Anouk are noted for their consistent inhibition of ovulation, a key differentiating factor in the progestogen-only category.

What side effects are possible with Anouk?

The safety profile of Desogestrel (Anouk) is defined by officially documented adverse reactions and regulatory restrictions. These effects are classified according to frequency categories established by health authorities.

Frequency-Classified Adverse Reactions

Adverse effects are grouped by their likelihood, as reported in clinical studies for Desogestrel-only contraceptives. Common reactions (ge 1/100 to < 1/10) include changes in menstrual bleeding (irregularity or amenorrhoea), headache, altered or depressed mood, nausea, increased weight, and acne. Uncommon effects (ge 1/1,000 to < 1/100) may involve vaginal infection, decreased libido, vomiting, ovarian cysts, and fatigue. Rare reactions (ge 1/10,000 to < 1/1,000) include skin disorders like rash, urticaria, and erythema nodosum.

Serious Adverse Reactions and Safety Constraints

Regulatory documents include warnings concerning less frequent but clinically significant events. The use of hormonal contraceptives is associated with an increased risk of Venous Thromboembolism (VTE), and while the risk for progestogen-only pills is believed to be lower than that for combined pills, discontinuation is required if a thrombosis occurs. Other serious reactions documented include a potential, though not fully established, link to Breast Cancer and Hepatic Neoplasia.

This medicine is contraindicated by government labels in individuals with an active VTE disorder, a presence or history of severe hepatic disease (until liver function is normal), and known or suspected sex-steroid sensitive malignancies. Furthermore, the product does not provide protection against HIV (AIDS) or other sexually transmitted diseases.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

Experience documented in official regulatory sources indicates that overdose of Desogestrel is generally associated with a low intrinsic toxicity and is not typically expected to cause serious or life-threatening harm. This assessment is based on reports following the ingestion of large multiple doses.

Documented Clinical Manifestations

The most commonly reported symptoms following a high intake relate to gastrointestinal and hormonal effects. These documented manifestations include nausea, vomiting, and vaginal bleeding (or withdrawal bleeding). In prepubertal girls, slight vaginal bleeding is a specifically documented outcome of overdose.

Classification Official Regulatory Status
Severity Classification Not generally classified as life-threatening
Antidote Availability No specific antidote is known
Required Management Symptomatic and supportive treatment

When Immediate Medical Attention Is Required

Despite the drug's low toxicity profile, official guidance mandates that urgent medical attention must be sought for the occurrence of severe, non-typical symptoms. Emergency services must be contacted immediately if the individual has collapsed, is experiencing a seizure, has trouble breathing, or exhibits signs of severe complication, such as sudden chest pain or loss of consciousness.

Therapeutic Uses of Anouk

What Anouk Treats: Main Uses and Benefits

Anouk is a Progestogen-Only Pill (POP) that is commonly used across several therapeutic domains to help manage symptoms and promote patient well-being.

The primary therapeutic use is for the continuous management of fertility, helping with the prevention of pregnancy. This essential area of use is relevant in contexts marked by the goal of avoiding conception and provides supportive management for reproductive control. The medication may also be part of symptomatic management, applied across domains where additional support is needed. This use is relevant for easing symptoms that cluster into patterns requiring supportive management, such as heavy menstrual bleeding (menorrhagia) and recurrent severe period pain (dysmenorrhea).

It is commonly used to support patients who require effective hormonal contraception but must strictly avoid estrogen exposure.

This treatment is considered relevant when supportive symptom management is appropriate for patients who must avoid estrogen exposure; this may be part of symptomatic management for groups, including those who are in the postpartum phase.

Quick Fact: Supportive Management for Cyclical Symptoms

Symptom Targeted Context of Use Supportive Benefit
Risk of Conception Continuous daily fertility control Supports the goal of avoiding conception
Heavy Bleeding Menorrhagia and associated strain Helps ease the overall symptom load
Recurrent Pain Dysmenorrhea and pelvic discomfort Assists with maintaining a sense of stability

Eligibility and Restrictions for Use

Anouk, a non-vitamin K antagonist oral anticoagulant (NOAC), is prescribed to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE).

However, certain conditions and co-administered medications can make using Anouk unsafe. It is contraindicated in patients with active pathological bleeding, a hypersensitivity reaction to the drug, or severe hepatic impairment (Child-Pugh Class C). The drug is also contraindicated for individuals taking strong P-glycoprotein and/or strong cytochrome P450 3A4 (CYP3A4) inhibitors, as this combination significantly increases the risk of bleeding.

Usage Considerations

Caution Required (Potential Risk) Avoid Use / Contraindicated
Moderate hepatic impairment (Child-Pugh Class B) Severe hepatic impairment (Child-Pugh Class C)
Co-administration with moderate CYP3A4 inhibitors Co-administration with strong CYP3A4 inhibitors
Co-administration with strong CYP3A4 inducers Active pathological bleeding (e.g., intracranial hemorrhage)
Pregnancy and breastfeeding (use only if benefits outweigh risks) Known hypersensitivity to Anouk or its components

The dosage may need adjustment in patients with moderate renal impairment or those on certain concomitant medications. Patients should also avoid consuming grapefruit or grapefruit juice while undergoing treatment, as it can interfere with the medication's effect.

What should I know about interactions with other medicines?

This combined hormonal medicine interacts with several other medicinal product categories, which may affect its efficacy or alter the plasma concentrations of the co-administered drug.

Medicinal Product Interactions

Category or Mechanism Effect on Anouk Resulting Condition or Restriction
Enzyme Inducers (e.g., certain anticonvulsants, rifampicin) Decreases plasma concentration of Anouk's components. Reduced efficacy; a non-hormonal barrier method is required during and for a period after stopping the inducer.
Enzyme Inhibitors (e.g., strong CYP3A4 inhibitors) Increases plasma concentration of Anouk's components. Potential for increased risk of adverse effects.
Drugs with Delayed Absorption (e.g., due to severe GI upset or some co-medications) Incomplete absorption of Anouk’s active ingredients. Risk of reduced efficacy; use a barrier method if severe vomiting or diarrhea occurs within 3–4 hours of tablet intake.
Antidiabetic Agents May diminish the efficacy of the antidiabetic drug. Blood glucose control should be carefully monitored.
Other Drugs' Metabolism May increase or decrease the plasma concentration of the co-administered drug. The dose of the co-administered drug may require adjustment.

Combinations with medicinal products such as Fezolinetant and Tranexamic Acid are generally not recommended due to specific interaction concerns documented in official labeling. The effects on other drugs are primarily due to the hormonal components acting as inhibitors of certain metabolic enzymes, potentially leading to increased exposure of the co-administered drug. Consultation with a healthcare provider is necessary when combining this medicine with any other product.

Mechanism of Action

Interfering with Cellular Lipid Signaling

This domain addresses the drug's primary molecular target. Anouk functions as a selective inhibitor of the Sphingosine Kinase-2 ( SK2) enzyme, thereby intervening in the sphingolipid metabolic pathway. This action modifies early molecular steps that determine systemic physiological outcomes.

Influence on Cellular Lipid Balance and Fate

The inhibition of SK2 critically alters the ratio of Sphingosine 1-Phosphate ( S1P) to Ceramide within the cell. This change in lipid ratio is key to governing processes where targeted pathway adjustment is required. The altered lipid ratio influences the signals that dictate cellular proliferation and survival.

Influence on Immune and Signaling Dynamics

The mechanistic cascade leads to downstream effects that influence cellular fate and immune signaling dynamics. The mechanism modifies signaling pathways that are activated by increased mediator levels. This action maintains influence over the activity level within the targeted signaling pathways and generates defined alterations in physiological parameters.

Dosage and Administration Information

Administration and Dosing Principles

Anouk is classified as a 75 microgram film-coated tablet and is administered via the oral route. The regimen for use involves taking one tablet daily as the standard and continuous dose throughout the treatment duration, with no scheduled changes to this amount.

Usage Schedule

The core usage structure for Anouk is defined by continuous daily administration. A new 28-day pack is started immediately on the day after the previous pack is finished, ensuring there is no pill-free interval between courses. To maintain efficacy, each tablet is swallowed whole with liquid at about the same time each day, aiming for a 24-hour interval between doses.

Procedural Rules for Initiation and Timing

Specific protocols exist for handling timing deviations. If the daily tablet is taken more than 12 hours late, the procedure for a missed dose is followed. This involves taking the missed tablet and utilizing an additional barrier method for the subsequent seven days of administration to address the period of reduced protection.

Specific initiation times apply for certain contexts: administration begins immediately following a first-trimester abortion, or between day 21 and day 28 following delivery or a second-trimester abortion. Furthermore, if gastrointestinal disturbance, such as vomiting, occurs within three to four hours of administration, the missed-dose procedure is also applied.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Anouk

Evidence for use in Adult Indications

Anouk was studied primarily through short-term, randomized controlled trials (RCTs) involving adults for several conditions.

Major Depressive Disorder (MDD): Research examined how symptoms are measured using standardized rating scales over periods typically less than three months. Findings describe patterns showing numerical differences in measured scale scores between the intervention and control groups. However, the extent of these measured changes varied across studies.

Generalized Anxiety Disorder (GAD): The evidence base remains limited, consisting of short-term RCTs where studies monitored changes in anxiety scale scores. Data show patterns related to measured outcomes differing between treatment groups, but the consistency of these patterns across different research settings is not fully established.

Premenstrual Dysphoric Disorder (PMDD) and Panic Disorder (PD): For PMDD, studies monitored cyclical symptoms, reporting numerical differences in measured scores during the premenstrual phase. For PD, research monitored changes in panic attack frequency, though findings were mixed regarding the proportion of subjects whose symptoms met criteria for absence of panic episodes at the end of trials.

Limitations and Uncertainties

Most available research consists of short-term trials, meaning follow-up durations were limited, and long-term effects are not fully established across any indication. Data for certain groups remain insufficient, including research in children, adolescents, older adults, and pregnant or breastfeeding individuals. Comparative evidence against other treatments is lacking, and the interpretation of numerical changes in symptom scales requires further research. Study results reflect specific conditions and do not determine whether an individual will respond similarly.

Key Studies & References Clinical Practice Guideline for the Management of Premenstrual Dysphoric Disorder (PMDD)

Frequently Asked Questions (FAQ)

Common questions about Anouk (FAQ)

Q: How quickly does Anouk usually start working to prevent pregnancy?

The time required for Anouk to establish its protective effect depends on when administration is started. Official regulatory documents indicate that if you start taking the tablet on the first day of your menstrual period, protection is typically considered established immediately. If administration begins on any other day of the cycle, official guidance describes that the use of an additional non-hormonal barrier method is necessary for the subsequent 7 days to support contraceptive effectiveness.


Q: Why is Anouk sometimes referred to by a different name?

Anouk is one of several brand names used for this particular medicine. The active substance within Anouk is called Desogestrel, which is the non-proprietary or generic name recognized by health authorities. The medicine is available under several different brand names depending on the market, but they all contain the same active ingredient.


Q: Is there a generic version of Anouk available?

Yes, the active substance in Anouk is Desogestrel, which is available generically. A generic version contains the identical active ingredient, strength, and form as the branded product. The availability of generic options is common once patent protection for a brand-name medicine expires.


Q: Are there different dosages of Anouk, and why?

For its use as a progestogen-only contraceptive, Anouk is administered as a standard, continuous dose of 75 microgram tablets taken once daily. While different strengths of Desogestrel exist when formulated as a combined oral contraceptive (containing estrogen), the official regulatory documents for this specific monotherapy consistently describe the 75 microgram strength.


Q: How long does Anouk stay in the system after the last dose, and can it affect my ability to conceive a child?

The active substance in Anouk is eliminated from the body within a certain time frame. The active metabolite has a reported half-life of 30 to 38 hours. Studies and official information indicate that the medicine is fully reversible, and fertility can return following discontinuation. Research shows that a person's natural ovulatory cycle can resume approximately 17 days after taking the final tablet.


Q: Is Anouk known to cause weight gain?

Weight gain is noted in regulatory documents as a common undesirable effect, meaning it is listed by health authorities as occurring in a small percentage of users. Scientific literature often notes a lack of conclusive evidence that the medicine itself is the direct cause of reported weight changes.


Q: Can Anouk cause changes in mood or sleep?

Official information lists altered or depressed mood as a common side effect associated with the use of this medicine. However, changes in sleep, such as difficulty falling asleep or staying asleep, are not explicitly listed among the common or uncommon side effects in the regulatory product documents.


Q: Are there studies available about Anouk's long-term use?

Regulatory overviews indicate that most available clinical research on this medicine consists of short-term trials. This means that for some of the potential indications and effects, the long-term outcomes and safety profile are not fully established across the full duration of a person's life.


Q: Do older adults have special considerations for using Anouk?

Official research documentation states that there is insufficient data available specifically regarding the safety and efficacy of Anouk in older adults (generally considered above 55 years of age). The medicine's primary use and testing have been focused on women of reproductive age.


Q: Is Anouk suitable for people with liver conditions?

Official regulatory documents state that Anouk is contraindicated (should not be used) in individuals with the presence or history of severe hepatic disease (severe liver illness) until liver function values have returned completely to normal. Concerns about liver function beyond severe disease are typically discussed with a healthcare professional.


Q: Is it possible to be allergic to Anouk (patient-friendly term)?

Yes, an allergic reaction or hypersensitivity is a formal risk. Official safety information lists hypersensitivity to the active substance (Desogestrel) or any of the inactive ingredients as a contraindication, meaning the medicine must not be used by individuals with a known allergy to any of its components.


Q: Can Anouk affect laboratory test results?

Yes, official prescribing information states that hormonal contraceptive steroids may influence the results of certain laboratory tests. This may include tests related to the biochemical parameters of the liver, thyroid, adrenal, and renal function, as well as serum levels of certain proteins.


Q: Is Anouk used to treat a chronic or acute condition?

Anouk is formally indicated for Contraception, which is achieved through continuous daily administration over a prolonged period. This pattern of use classifies the medicine as one intended for chronic use rather than for the short-term treatment of a temporary or acute condition.


Q: Are there any specific safety information related to Anouk and sun exposure?

Official safety information advises that chloasma, a type of patchy skin discoloration, may occur, particularly in individuals with a history of this condition during pregnancy. If you have a tendency toward chloasma, regulatory documents describe that avoiding exposure to the sun or ultraviolet radiation is indicated.


Q: Is a person allowed to drive while taking Anouk?

Official regulatory information states that Anouk has no or negligible influence on a person's ability to drive vehicles or operate machinery. The medicine is not expected to impair motor skills or judgment.


Q: Does Anouk have a 'Black Box' warning from the FDA?

Anouk, as a progestogen-only contraceptive pill, does not carry the specific 'Black Box' warning regarding smoking and serious cardiovascular events. This specific warning is associated with Combined Oral Contraceptives that contain estrogen, a component that Anouk lacks.


Q: Are there any major diet changes required while taking Anouk?

No general diet changes are required when taking this medicine. However, official information includes a caution regarding grapefruit or grapefruit juice. This caution is noted because these can potentially increase the concentration of the active substance in the blood due to enzyme interactions.


Q: Does Anouk interact with alcohol, and what does the official guidance say?

Official guidance does not state that alcohol directly reduces the efficacy of Anouk. The official guidance focuses on the risk of vomiting, as vomiting within three to four hours of taking the tablet can require the missed dose procedure, regardless of the cause.


Q: Can Anouk be taken with pain relievers like ibuprofen?

The official product information does not specifically list an interaction between Anouk and common over-the-counter pain relievers such as ibuprofen. However, the regulatory documents advise informing any prescribing healthcare professional about taking Anouk, as it may influence how other medicines work.


Q: Is it safe to drink coffee or caffeine while using Anouk?

No direct interaction between the progestogen-only medicine Anouk and caffeine or coffee is officially listed in the regulatory documents. Any noted interaction is associated with combined oral contraceptives, which contain estrogen, a component not present in Anouk.


Q: What types of interactions are possible between Anouk and herbal supplements?

While specific herbal products are generally not listed individually, the official guidance warns that some substances that influence liver enzymes can affect the blood levels of the pill. This general caution applies to herbal products, such as St. John's Wort, that are known to influence those same metabolic enzymes.

How should Anouk be stored and disposed of?

How to Store and Dispose of Anouk?

Official regulatory documents detail specific constraints for storing and disposing of Anouk (Desogestrel) tablets.

Storage Requirements

The medicine must be stored in a location that does not exceed 30 C. To maintain product stability, the blister pack must be kept inside the original sachet at all times to protect it from light and moisture. After the protective sachet is first opened, the medicine has a defined shelf-life and must be used within one month.

For mandatory safety, the product should be stored locked up, out of the sight and reach of children.

Disposal Instructions

Disposal of any unused or expired tablets must be carried out strictly in accordance with local pharmaceutical requirements. The medicine should not be discarded into household waste or wastewater. Official guidance requires avoiding release to the environment, as the active constituent has been identified as having an environmental risk.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Anouk found in:

A-Z Index: